Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2002
05/30/2002WO2002041915A1 A composition of sodium channel blocking compound
05/30/2002WO2002041910A2 Methods and compositions for the treatment of diseases of the eye
05/30/2002WO2002041909A1 Method and preparations having effect against allergic symptoms
05/30/2002WO2002041907A1 The additive in food, drug, cosmetics for supplying $g(g) linolenic acid and the process of producing them
05/30/2002WO2002041903A1 The composition of multipurpose high functional alkaline solution composition, preparation thereof, and for the use of nonspecific immunostimulator
05/30/2002WO2002041902A1 Treatment of disorders using polyethylenimine diazeniumdiolate
05/30/2002WO2002041901A1 Treatment of osteoporosis
05/30/2002WO2002041900A1 Preparation for strengthening the immune response in the waldeyer's ring and the oronasal mucosa by intranasal administration
05/30/2002WO2002041899A1 An antibiotic/analgesic formulation and a method of making this formulation
05/30/2002WO2002041898A2 Antibacterial methods and screens
05/30/2002WO2002041897A2 Novel pharmaceutical compositions with anti-diabetic activity and method for preparing same
05/30/2002WO2002041896A2 Use of thienopyrimidines
05/30/2002WO2002041895A1 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
05/30/2002WO2002041894A2 Selective dopamine d4 receptor agonists for treating sexual dysfunction
05/30/2002WO2002041893A1 Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
05/30/2002WO2002041892A1 Water-soluble liquid internal medicine
05/30/2002WO2002041891A2 Hiv treatment with benzimidazoles
05/30/2002WO2002041890A1 Medicinal compositions
05/30/2002WO2002041889A2 Indolsulfonyl compounds useful in the treatment of cns disorders
05/30/2002WO2002041888A1 Anticancer agent comprising mycolactone
05/30/2002WO2002041887A1 Dry syrup preparations
05/30/2002WO2002041886A1 Ydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections
05/30/2002WO2002041884A2 Inhibitors of abc drug transporters at the blood-brain barrier
05/30/2002WO2002041883A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
05/30/2002WO2002041882A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
05/30/2002WO2002041881A2 Repinotan kit
05/30/2002WO2002041880A2 Use of pyrazolo[4,3-d]pyrimidines
05/30/2002WO2002041879A2 Antidiabetic compositions containing a biguanide and a sulfonamide
05/30/2002WO2002041878A2 Titratable dosage transdermal delivery system
05/30/2002WO2002041876A1 Pharmaceutical composition for controlled release of an active ingredient
05/30/2002WO2002041871A2 Composition comprising an imexon or derivatives thereof and lipids
05/30/2002WO2002041865A1 Cosmetic method of treating skin
05/30/2002WO2002041861A1 Rhinological agents
05/30/2002WO2002041853A1 O/w emulsion composition and method of preparing the same
05/30/2002WO2002041843A2 Antiinflammation agents
05/30/2002WO2002041841A2 Compositions for adhesion prevention
05/30/2002WO2002041840A2 Sildenafil citrate chewing gum formulations and methods of using the same
05/30/2002WO2002041837A2 Treatment of mucositis
05/30/2002WO2002041835A2 Estrogen receptor modulators
05/30/2002WO2002041834A2 Atorvastatin hemi-calcium form vii
05/30/2002WO2002041832A2 Compositions having comfrey and methods for reducing retinoid-induced skin irritation
05/30/2002WO2002041831A2 Inositol derivatives for increasing chloride secretion and inhibiting inflammation
05/30/2002WO2002041828A2 Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
05/30/2002WO2002041827A2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
05/30/2002WO2002028440B1 Methods and compositions for modulating t cell activation and uses thereof
05/30/2002WO2002026242A3 Inhibition of systemic infections in humans and vertebrates by dietary fibers
05/30/2002WO2002022599A3 Chemokine receptor binding heterocyclic compounds
05/30/2002WO2002020526A3 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
05/30/2002WO2002016357A3 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
05/30/2002WO2002016333A3 Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
05/30/2002WO2002014264A3 (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
05/30/2002WO2002013805A3 Method of treating neurodegenerative disorders of the retina and optic nerve head
05/30/2002WO2002012444A3 Amniotic apoptosis modulating substances
05/30/2002WO2002011550A3 Oil/fat composition
05/30/2002WO2002009664A3 Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations
05/30/2002WO2002009643A3 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
05/30/2002WO2002007822A3 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
05/30/2002WO2002007677A3 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
05/30/2002WO2002005792A3 Use of matrix metalloprotease inhibitors for the treatment of cancer
05/30/2002WO2002004444A3 Heterocycle carboxamides as antiviral agents
05/30/2002WO2002004034A3 Polymer-bound metal-containing compositions
05/30/2002WO2002002565A3 Glucocortiocoid-selective antiinflammatory agents
05/30/2002WO2002000663A3 Polycyclic xanthones as antibiotics
05/30/2002WO2002000611A3 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/30/2002WO2001098270A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
05/30/2002WO2001097778A3 Amphotericin b structured emulsion
05/30/2002WO2001097775A3 Controlled release anti-inflammatory formulation
05/30/2002WO2001095894A3 Topical water-based anti-inflammatory compositions
05/30/2002WO2001092580A3 Lyophilizable and enhanced compacted nucleic acids
05/30/2002WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
05/30/2002WO2001092274A3 Naaladase inhibitors for treating retinal disorders and glaucoma
05/30/2002WO2001091789A3 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
05/30/2002WO2001091737A3 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides
05/30/2002WO2001091724A3 Transdermal delivery of lasofoxifene
05/30/2002WO2001089495A3 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
05/30/2002WO2001087934A3 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
05/30/2002WO2001087913A3 Method for treating retinal degeneration with purinergic receptor agonists
05/30/2002WO2001085686A3 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes
05/30/2002WO2001085149A3 Felbamate derived compounds
05/30/2002WO2001082967A8 MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION
05/30/2002WO2001078700A3 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine
05/30/2002WO2001078683A3 Sustained release formulations comprising growth hormone
05/30/2002WO2001077055A3 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
05/30/2002WO2001074780A8 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
05/30/2002WO2001074390A3 The use of a calcium channel blocker for treating renal disorders
05/30/2002WO2001072714A3 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
05/30/2002WO2001064877A3 Human schizophrenia gene
05/30/2002WO2001060343A3 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
05/30/2002WO2001051043A3 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
05/30/2002WO2001050994A8 Topical medicated bioadhesive compositions and methods of use and preparation thereof
05/30/2002WO2001042273A3 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
05/30/2002WO2001040223B1 Aminoheterocyclylamides as pesticides and antiparasitic agents
05/30/2002WO2001037781A8 A stable aqueous dispersion of nutrients
05/30/2002WO2001023405A3 Therapeutic treatment of androgen receptor driven conditions
05/30/2002WO2001021160B1 Carboxymide and aniline derivatives as selective inhibitors of pathogens
05/30/2002WO2000078296A3 Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
05/30/2002WO2000076489A3 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
05/30/2002WO2000066581A8 Cyanopyrroles as progesterone receptor agonists
05/30/2002WO2000066225A8 Contraceptive compositions containing cyclic carbamates and amide derivatives
05/30/2002WO2000052205A8 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE